Temporary pause in new enrolments for LAVENDER trial in US
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren to capture substantially greater value after Phase 3
- Compelling results for 2591 dose ranging study in PMS model
- Commentary on potential benefit to Neuren of RPD designation
- Rare Pediatric Disease designation received from FDA
- Appendix 4E and 2019 full year accounts
Later from Neuren Pharmaceuticals
- First patent in Israel granted for trofinetide
- Q1 2020 Activity Report
- Appendix 4C - quarterly
- Neuren commences first clinical trial for NNZ-2591
- Neuren announces changes to leadership team
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals